30-year-old man receives first dose in human trials of indigenous COVID-19 vaccine Covaxin
The All India Institute of Medical Sciences (AIIMS), Delhi, is one 12 institutions where human trials are being conducted
A 30-year-old man was given the first dose of undertrial COVID-19 vaccine Covaxin at the All India Institute of Medical Sciences (AIIMS) in Delhi on Friday.
According to a report in NDTV, 12 volunteers were also called for a series of pre-tests including blood and nasopharyngeal testing for COVID-19. Doctors selected 10 healthy individuals, after the results, for the vaccine to be given in phases.
A report on their health condition, after the first dose, will be submitted to the ethics committee, which will review the entire process. NDTV said about 100 healthy people will be vaccinated at AIIMS as part of the trial.
Hyderabad-based Bharat Biotech has developed Covaxin in collaboration with the ICMR and the National Institute of Virology (NIV). The Drugs Controller General of India (GCGI) had recently given the collaboration the go ahead to conduct human trials.
Phase 1 of the vaccine trial, as per the report, will be conducted on healthy people aged between 18 and 55, having no co-morbid conditions.
The first phase of the trial will also include women with no pregnancy. For the second phase, 750 people will be recruited between the ages of 12 and 65.
The NDTV report quoted AIIMS Director Dr Randeep Guleria as saying that about 1,800 volunteers had already registered to be part of the trial at AIIMS. He said their primary responsibility is the safety of the vaccine.
Read the complete report in NDTV